Developer docs
API playgroundTry for free, no card

Search company profiles

ElevateBio

Full company profile

uuid0000nkz

Namestring
ElevateBio
Legal namestring
ElevateBio
Websiteurl
elevate.bio
Company typeenum
Private
Founded yearint
2017
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy manufacturing, gene editing services, viral vector production, cGMP biomanufacturing, advanced therapy CDMO
Industry5 codes
PRIMARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Cell and Gene Therapy CDMO
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1CDMO Manufacturing Services
TypeProfessional Services
Description

Contract development and manufacturing services for cell therapies, viral vectors (lentiviral and AAV), and mRNA. Services span from preclinical through commercial cGMP manufacturing, with dedicated manufacturing suites and integrated process development, analytical, and regulatory support.

elevate.bio
2Gene Editing Discovery Services
TypeProfessional Services
Description

Partner access to proprietary gene editing technologies and discovery-stage expertise, including proof-of-concept studies, candidate engineering, and clinical lead optimization services.

elevate.bio
3Technology Licensing
TypeLicensing Royalties
Description

Licensing of proprietary technologies including iPSC lines, gene editing tools, and delivery platforms to biopharmaceutical partners for their therapeutic programs.

elevate.bio
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Infrastructure, Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Life Edit
Description

Gene editing platform providing CRISPR systems and novel editing technologies including nucleases, base editors, and epigenetic editors for flexible genome access

elevate.bio
+3 more records
Core offering1 text field

ElevateBio is a technology-driven advanced therapy Contract Development and Manufacturing Organization (CDMO) that partners with biopharmaceutical companies to develop and manufacture cell and gene therapies. The company operates an integrated platform spanning proprietary gene editing technologies across five editing modalities, AI-powered protein discovery, and cGMP manufacturing capabilities for cell therapies, viral vectors, and mRNA. Services cover the full development journey from early discovery and process development through clinical supply and commercial manufacturing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 98% manufacturing batch success rate in 2025
+4 more records
Product overview1 text field

ElevateBio is a technology-driven advanced therapy CDMO offering an integrated platform spanning gene editing technologies, discovery services, and cGMP manufacturing capabilities. The core offering consists of Gene Editing Design & Optimization Services (covering five editing modalities: nuclease editing, base editing, RT editing, epigenetic editing, and targeted gene insertion) paired with manufacturing services (cGMP Manufacturing, Process Development, Analytical Development, Next-Generation Sequencing, Quality, and Regulatory CMC). The technology portfolio includes proprietary platforms: the Gene Editing Technology Platform, LentiPeak Lentiviral Vector Platform, AAV Platform, LNP Delivery Platform, mRNA Platform, and iPSC Platform. A Generative AI Platform enables AI-powered protein discovery and optimization. The company operates two BaseCamp manufacturing facilities in Waltham, MA and Pittsburgh, PA, providing end-to-end services from discovery through commercialization for cell therapies, viral vectors, and mRNA.

Product and service7 records
1Gene Editing Design & Optimization Services
CategoryDiscovery and Optimization
Description

Comprehensive gene editing services spanning five editing modalities including nuclease editing, base editing, reverse transcriptase editing, epigenetic editing, and targeted gene insertion for both ex vivo and in vivo therapeutic applications; serves biopharmaceutical developers of cell and gene therapies.

2cGMP Manufacturing Services
CategoryContract Manufacturing
Description

Clinical and commercial cGMP manufacturing across three modalities: cell therapies (autologous and allogeneic), viral vectors (lentiviral and AAV), and mRNA; provided at purpose-built BaseCamp facilities for biopharmaceutical partners.

3Process Development Services
CategoryProcess Development
Description

Cell and gene therapy process development spanning optimization, scale-up, process characterization, and process validation with platform processes for cell therapy and viral vector manufacturing; serves advanced therapy developers.

4Analytical Development Services
CategoryAnalytical Development
Description

Customized analytical assay development for cell therapies and viral vectors including assay development, stability testing, and platform assays for product safety, potency, purity, and identity; serves biopharmaceutical partners.

5Next-Generation Sequencing Services
CategoryGenomics Services
Description

Comprehensive NGS services including amplicon, whole exome, whole genome, RNA (including single-cell), methyl, and complete plasmid sequencing with integrated bioinformatics analysis; serves gene therapy and cell therapy developers.

6Quality Services
CategoryQuality Assurance
Description

Quality assurance and validation, product QC release testing with 40+ in-house state-of-the-art quality control release methods, supporting in-process control and cGMP product release for advanced therapy developers.

7Regulatory CMC Services
CategoryRegulatory Affairs
Description

Regulatory affairs support across preclinical, clinical, and commercial stages including regulatory filing preparation, Module 3 Quality sections, and health authority interactions; serves biopharmaceutical and biotech clients.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2026-03-17
Description

Pilot partnership for Eveo Cell Therapy Platform - an integrated automated system for autologous cell therapy manufacturing. Demonstrated nearly fourfold capacity increase and ~90% cost reduction. ElevateBio as preferred early-access partner with orders starting September 2026.

2PathmakerBio Consortium
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-02
Description

Partnership with Northeastern University, Bridgewater State University, and BioConnects New England to launch biomanufacturing training program (PathmakerBio) providing hands-on training in protein and cell/gene therapy manufacturing for underserved communities.

citybiz.co
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-09-26
Description

Manufacturing partnership for Kyverna's Ingenui-T cell therapy, advancing cell therapy programs for autoimmune diseases using ElevateBio's manufacturing expertise.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-24
Description

Multi-target R&D collaboration worth up to ~$1.9 billion to discover and develop gene editing therapies for rare and cardiometabolic diseases. Leverages ElevateBio's Life Edit gene editing technologies and manufacturing capabilities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-03-10
Description

Multi-year collaboration leveraging generative AI and cloud computing to expand and accelerate CRISPR discovery, design, and drug development for complex monogenic and polygenic diseases. Uses protein language models trained on ElevateBio's proprietary protein databases.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-22
Description

Strategic collaboration to accelerate development of novel in vivo gene editing therapies. Combines Moderna's mRNA expertise with ElevateBio's Life Edit gene editing technologies and delivery platforms.

7Affini-T Therapeutics
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-11-15
Description

Partnership to advance Affini-T's T cell therapy programs targeting core oncogenic drivers, leveraging ElevateBio's manufacturing and gene editing capabilities.

elevate.bio
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-08-25
Description

30-year strategic partnership to establish Pitt BioForge Biomanufacturing Center at Hazelwood Green in Pittsburgh. ElevateBio to operate manufacturing facilities within the facility for cell and gene therapy development, backed by $100M grant from Richard King Mellon Foundation.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-08-23
Description

Partnership to accelerate development of regenerative medicines, providing manufacturing support for cell and gene therapy programs advancing through clinical development.

10George Daley / Boston Children's Hospital
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-08-04
Description

Formation of new company with George Daley (Harvard Medical School) and Boston Children's Hospital to develop iPSC-derived allogeneic immune therapies, combining academic research with ElevateBio's manufacturing platform.

elevate.bio
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-06-29
Description

Five-year cell and gene therapy collaboration to advance development of novel therapies. Combines clinical insights with ElevateBio's manufacturing capabilities.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-07-25
Description

10-year alliance agreement for ElevateBio BaseCamp to manufacture innovative cell and gene therapies developed by MGH researchers and clinicians.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Manufacturing collaboration for base editing therapies where ElevateBio helped establish the manufacturing blueprint for a novel class of gene-edited therapy.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Viral vector and gene therapy CDMO offering process development, analytical, and cGMP manufacturing services for gene therapy developers. Comparable to ElevateBio's lentiviral and AAV vector CDMO business.

TypeDirect peer
Description

Technology-focused biomanufacturing company with cell and gene therapy manufacturing capabilities serving biotech and pharma clients. Comparable to ElevateBio as a purpose-built advanced therapy manufacturing partner.

TypeDirect peer
Description

Cell and gene therapy CDMO specializing in viral vector and cell therapy manufacturing, formed through Yposkesi's acquisition and integration. Comparable to ElevateBio's viral vector and cell therapy CDMO focus.

TypeDirect peer
Description

Global CDMO leader with a substantial cell and gene therapy manufacturing franchise offering viral vector, cell therapy, and integrated process development services. Directly comparable to ElevateBio across lentiviral/AAV vector manufacturing and autologous/allogeneic cell therapy capabilities.

TypeDirect peer
Description

Major cell and gene therapy CDMO with viral vector and cell therapy manufacturing services across multiple global sites. Closely comparable to ElevateBio's BaseCamp model for clinical and commercial cGMP production of advanced therapies.

TypeDirect peer
Description

Specialist lentiviral vector CDMO providing process development and GMP manufacturing services for cell and gene therapy developers. Highly comparable to ElevateBio's LentiPeak platform and lentiviral vector CDMO offering.

TypeDirect peer
Description

CDMO with growing cell and gene therapy manufacturing capabilities alongside broader biologics and viral vector services. Comparable to ElevateBio as a multi-modality CDMO partner (and notably a fellow member of the Akadeum CDMO Alliance with ElevateBio).

TypeDirect peer
Description

CDMO offering cell therapy, viral vector, and gene therapy manufacturing services globally. Comparable to ElevateBio's integrated CDMO model for advanced therapy developers.

TypeBroad incumbent
Description

Diversified life sciences CDMO and tools provider whose pharma services segment includes cell and gene therapy manufacturing. Overlaps with ElevateBio's CDMO offering but as part of a much broader portfolio.

TypeDirect peer
Description

Cell and gene therapy CDMO offering viral vector, cell therapy, and plasmid manufacturing services. Directly comparable to ElevateBio's advanced therapy CDMO capabilities across modalities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment4 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ElevateBio

Cell and Gene Therapy CDMOelevate.bio

ElevateBio firmographics

Firmographics
Name
ElevateBio
Legal name
ElevateBio
Website
https://elevate.bio
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
251–500 employees
Ownership category
akta.pro rank

ElevateBio industry classification

Industry
Product category
Cell and Gene Therapy CDMO
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Cell therapy manufacturing
  • Gene editing services
  • Viral vector production
  • CGMP biomanufacturing
  • Advanced therapy CDMO

Where ElevateBio is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices4 records

Markets served

ElevateBio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Infrastructure, Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. CDMO Manufacturing Services: Contract development and manufacturing services for cell therapies, viral vectors (lentiviral and AAV), and mRNA. Services span from preclinical through commercial cGMP manufacturing, with dedicated manufacturing suites and integrated process development, analytical, and regulatory support.
  2. Gene Editing Discovery Services: Partner access to proprietary gene editing technologies and discovery-stage expertise, including proof-of-concept studies, candidate engineering, and clinical lead optimization services.
  3. Technology Licensing: Licensing of proprietary technologies including iPSC lines, gene editing tools, and delivery platforms to biopharmaceutical partners for their therapeutic programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

ElevateBio product offering

Product offering

Core offering

ElevateBio is a technology-driven advanced therapy Contract Development and Manufacturing Organization (CDMO) that partners with biopharmaceutical companies to develop and manufacture cell and gene therapies. The company operates an integrated platform spanning proprietary gene editing technologies across five editing modalities, AI-powered protein discovery, and cGMP manufacturing capabilities for cell therapies, viral vectors, and mRNA. Services cover the full development journey from early discovery and process development through clinical supply and commercial manufacturing.

Product overview

ElevateBio is a technology-driven advanced therapy CDMO offering an integrated platform spanning gene editing technologies, discovery services, and cGMP manufacturing capabilities. The core offering consists of Gene Editing Design & Optimization Services (covering five editing modalities: nuclease editing, base editing, RT editing, epigenetic editing, and targeted gene insertion) paired with manufacturing services (cGMP Manufacturing, Process Development, Analytical Development, Next-Generation Sequencing, Quality, and Regulatory CMC). The technology portfolio includes proprietary platforms: the Gene Editing Technology Platform, LentiPeak Lentiviral Vector Platform, AAV Platform, LNP Delivery Platform, mRNA Platform, and iPSC Platform. A Generative AI Platform enables AI-powered protein discovery and optimization. The company operates two BaseCamp manufacturing facilities in Waltham, MA and Pittsburgh, PA, providing end-to-end services from discovery through commercialization for cell therapies, viral vectors, and mRNA.

Differentiator

Problem solved

Functional benefit

Brands

  • Life Edit: Gene editing platform providing CRISPR systems and novel editing technologies including nucleases, base editors, and epigenetic editors for flexible genome access
  • HighPassBio
  • BaseCamp
  • LentiPeak

Products and services

  • Gene Editing Design & Optimization Services Comprehensive gene editing services spanning five editing modalities including nuclease editing, base editing, reverse transcriptase editing, epigenetic editing, and targeted gene insertion for both ex vivo and in vivo therapeutic applications; serves biopharmaceutical developers of cell and gene therapies.
  • cGMP Manufacturing Services Clinical and commercial cGMP manufacturing across three modalities: cell therapies (autologous and allogeneic), viral vectors (lentiviral and AAV), and mRNA; provided at purpose-built BaseCamp facilities for biopharmaceutical partners.
  • Process Development Services Cell and gene therapy process development spanning optimization, scale-up, process characterization, and process validation with platform processes for cell therapy and viral vector manufacturing; serves advanced therapy developers.
  • Analytical Development Services Customized analytical assay development for cell therapies and viral vectors including assay development, stability testing, and platform assays for product safety, potency, purity, and identity; serves biopharmaceutical partners.
  • Next-Generation Sequencing Services Comprehensive NGS services including amplicon, whole exome, whole genome, RNA (including single-cell), methyl, and complete plasmid sequencing with integrated bioinformatics analysis; serves gene therapy and cell therapy developers.
  • Quality Services Quality assurance and validation, product QC release testing with 40+ in-house state-of-the-art quality control release methods, supporting in-process control and cGMP product release for advanced therapy developers.
  • Regulatory CMC Services Regulatory affairs support across preclinical, clinical, and commercial stages including regulatory filing preparation, Module 3 Quality sections, and health authority interactions; serves biopharmaceutical and biotech clients.

Quantifiable outcome

  • 98% manufacturing batch success rate in 2025
  • +4 more outcomes

Companies that use ElevateBio

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

ElevateBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature8 records

ElevateBio partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered major, minor and core.

  • SartoriusmajorTechnology or Integration · 17 March 2026Pilot partnership for Eveo Cell Therapy Platform - an integrated automated system for autologous cell therapy manufacturing. Demonstrated nearly fourfold capacity increase and ~90% cost reduction. ElevateBio as preferred early-access partner with orders starting September 2026.
  • PathmakerBio ConsortiumminorStrategic or Co-development Partner · 2 January 2025Partnership with Northeastern University, Bridgewater State University, and BioConnects New England to launch biomanufacturing training program (PathmakerBio) providing hands-on training in protein and cell/gene therapy manufacturing for underserved communities.
  • Kyverna TherapeuticsmajorStrategic or Co-development Partner · 26 September 2023Manufacturing partnership for Kyverna's Ingenui-T cell therapy, advancing cell therapy programs for autoimmune diseases using ElevateBio's manufacturing expertise.
  • Novo NordiskcoreStrategic or Co-development Partner · 24 May 2023Multi-target R&D collaboration worth up to ~$1.9 billion to discover and develop gene editing therapies for rare and cardiometabolic diseases. Leverages ElevateBio's Life Edit gene editing technologies and manufacturing capabilities.
  • Amazon Web Services (AWS)coreTechnology or Integration · 10 March 2023Multi-year collaboration leveraging generative AI and cloud computing to expand and accelerate CRISPR discovery, design, and drug development for complex monogenic and polygenic diseases. Uses protein language models trained on ElevateBio's proprietary protein databases.
  • ModernacoreStrategic or Co-development Partner · 22 February 2023Strategic collaboration to accelerate development of novel in vivo gene editing therapies. Combines Moderna's mRNA expertise with ElevateBio's Life Edit gene editing technologies and delivery platforms.
  • Affini-T TherapeuticsmajorStrategic or Co-development Partner · 15 November 2022Partnership to advance Affini-T's T cell therapy programs targeting core oncogenic drivers, leveraging ElevateBio's manufacturing and gene editing capabilities.
  • University of PittsburghcoreStrategic or Co-development Partner · 25 August 202230-year strategic partnership to establish Pitt BioForge Biomanufacturing Center at Hazelwood Green in Pittsburgh. ElevateBio to operate manufacturing facilities within the facility for cell and gene therapy development, backed by $100M grant from Richard King Mellon Foundation.
  • California Institute for Regenerative Medicine (CIRM)majorStrategic or Co-development Partner · 23 August 2022Partnership to accelerate development of regenerative medicines, providing manufacturing support for cell and gene therapy programs advancing through clinical development.
  • George Daley / Boston Children's HospitalmajorStrategic or Co-development Partner · 4 August 2022Formation of new company with George Daley (Harvard Medical School) and Boston Children's Hospital to develop iPSC-derived allogeneic immune therapies, combining academic research with ElevateBio's manufacturing platform.
  • Boston Children's HospitalmajorStrategic or Co-development Partner · 29 June 2021Five-year cell and gene therapy collaboration to advance development of novel therapies. Combines clinical insights with ElevateBio's manufacturing capabilities.
  • Massachusetts General HospitalmajorStrategic or Co-development Partner · 25 July 202010-year alliance agreement for ElevateBio BaseCamp to manufacture innovative cell and gene therapies developed by MGH researchers and clinicians.
  • Beam TherapeuticsmajorStrategic or Co-development PartnerManufacturing collaboration for base editing therapies where ElevateBio helped establish the manufacturing blueprint for a novel class of gene-edited therapy.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

ElevateBio competitors and assessment

Company assessment

Direct peers

  • Genezen: Viral vector and gene therapy CDMO offering process development, analytical, and cGMP manufacturing services for gene therapy developers. Comparable to ElevateBio's lentiviral and AAV vector CDMO business.
  • National Resilience: Technology-focused biomanufacturing company with cell and gene therapy manufacturing capabilities serving biotech and pharma clients. Comparable to ElevateBio as a purpose-built advanced therapy manufacturing partner.
  • SK Pharmteco (Yposkesi): Cell and gene therapy CDMO specializing in viral vector and cell therapy manufacturing, formed through Yposkesi's acquisition and integration. Comparable to ElevateBio's viral vector and cell therapy CDMO focus.
  • Lonza: Global CDMO leader with a substantial cell and gene therapy manufacturing franchise offering viral vector, cell therapy, and integrated process development services. Directly comparable to ElevateBio across lentiviral/AAV vector manufacturing and autologous/allogeneic cell therapy capabilities.
  • Catalent (Novo Holdings): Major cell and gene therapy CDMO with viral vector and cell therapy manufacturing services across multiple global sites. Closely comparable to ElevateBio's BaseCamp model for clinical and commercial cGMP production of advanced therapies.
  • Oxford BioMedica: Specialist lentiviral vector CDMO providing process development and GMP manufacturing services for cell and gene therapy developers. Highly comparable to ElevateBio's LentiPeak platform and lentiviral vector CDMO offering.
  • Charles River Laboratories: CDMO with growing cell and gene therapy manufacturing capabilities alongside broader biologics and viral vector services. Comparable to ElevateBio as a multi-modality CDMO partner (and notably a fellow member of the Akadeum CDMO Alliance with ElevateBio).
  • AGC Biologics: CDMO offering cell therapy, viral vector, and gene therapy manufacturing services globally. Comparable to ElevateBio's integrated CDMO model for advanced therapy developers.
  • WuXi Advanced Therapies: Cell and gene therapy CDMO offering viral vector, cell therapy, and plasmid manufacturing services. Directly comparable to ElevateBio's advanced therapy CDMO capabilities across modalities.

Broad incumbents

  • Thermo Fisher Scientific (Patheon): Diversified life sciences CDMO and tools provider whose pharma services segment includes cell and gene therapy manufacturing. Overlaps with ElevateBio's CDMO offering but as part of a much broader portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

ElevateBio social profiles

Digital presence

ElevateBio compliance and trust

Trust signal

Compliance3 records

ElevateBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ElevateBio leadership team

Management profile

Number of profiles

Profiles17 records

ElevateBio subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

ElevateBio funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ElevateBio M&A and investment

M&A and investment

M&A1 record

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ElevateBio

What does ElevateBio do?

ElevateBio is a technology-driven advanced therapy Contract Development and Manufacturing Organization (CDMO) that partners with biopharmaceutical companies to develop and manufacture cell and gene therapies. The company operates an integrated platform spanning proprietary gene editing technologies across five editing modalities, AI-powered protein discovery, and cGMP manufacturing capabilities for cell therapies, viral vectors, and mRNA. Services cover the full development journey from early discovery and process development through clinical supply and commercial manufacturing.

Is ElevateBio a public or private company?

ElevateBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was ElevateBio founded?

ElevateBio was founded in 2017. It employs 251 to 500 people.

Where is ElevateBio based?

ElevateBio is headquartered in Waltham, United States, in the North America region.

How does ElevateBio make money?

Three revenue lines are on record. CDMO Manufacturing Services are the primary driver. The others are gene Editing Discovery Services and technology Licensing.

Who are ElevateBio's main competitors?

Direct peers on record are Genezen, National Resilience, SK Pharmteco (Yposkesi), Lonza, Catalent (Novo Holdings), Oxford BioMedica, Charles River Laboratories, AGC Biologics and WuXi Advanced Therapies. Thermo Fisher Scientific (Patheon) is listed as a broad incumbent.

Does ElevateBio have an API?

No public API is recorded for ElevateBio.

What industry is ElevateBio in?

ElevateBio's product category is Cell and Gene Therapy CDMO. Its primary akta.pro industry code is HLAAACAJ, Gene Therapy Vector Manufacturing & CDMO Services, with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American City Business JournalsBioForge anchor tenant ElevateBio names new COOElevateBio, the primary anchor tenant of the under-construction BioForge facility in Hazelwood Green, has named Steve Falcone as its new COO. Falcone previously worked with CEO Chris Murphy at Brammer Bio and Thermo Fisher Scientific.BioProcess InternationalElevateBio adds genome tech with Life Edit buyElevateBio acquired all of AgBiome's shares of Life Edit Therapeutics, combining its genome editing capabilities with its iPSC and cellular engineering platforms. The deal aims to accelerate in vivo gene editing therapeutics, with Life Edit continuing operations in North Carolina.BioSpaceCabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business UpdateCabaletta Bio reported Q2 2026 financial results, with R&D expenses of $44.4 million and cash of $225.1 million. The company plans to report registrational RESET-Myositis data in mid-2027 to support a BLA submission in H2 2027, and initiated a SSc-associated ILD registrational study in 4Q26.WesanewsPittsburgh set to become rare disease research hub with $25M investmentPittsburgh is launching a new initiative focused on developing therapies for rare diseases, supported by a $25 million investment from the Richard King Mellon Foundation and involving multiple research organizations. The collaboration includes the University of Pittsburgh Health Sciences, UPMC facilities, and ElevateBio, aiming to create a venture philanthropy platform called Rare Ventures that will accelerate the development of treatments for over 10,000 rare diseases.Seeking AlphaKyverna Therapeutics: 'Strong Buy' On ElevateBio Deal And RA Program AdvancementKyverna Therapeutics is recommended as a "Strong Buy" based on its cell therapy miv-cel advancing across three indications—SPS, gMG, and refractory RA—with positive clinical data from phase 2 trials. The company has initiated a rolling BLA submission for miv-cel in SPS targeting completion by Q4 2026, supported by positive KYSA-8 results. A manufacturing agreement with ElevateBio secures supply chain capacity to support U.S. and global commercialization and expansion into additional indications.GlobeNewswireKyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-celKyverna Therapeutics and ElevateBio announced a manufacturing agreement for miv-cel, covering U.S. commercial and global clinical supply. The deal supports Kyverna's potential launches in stiff person syndrome and generalized myasthenia gravis, with Kyverna on track to complete its rolling BLA submission in Q4 2026.The Pharma LetterKyverna and ElevateBio collaborate on miv-celKyverna Therapeutics and ElevateBio have entered a manufacturing agreement for miv-cel (mivocabtagene autoleucel), Kyverna's CD19-directed CAR T-cell therapy, covering both US commercial and global clinical supply. The agreement provides Kyverna with flexible and scalable manufacturing capacity to support potential launches in stiff person syndrome and generalized myasthenia gravis, with the company's shares rising 3.2% to $7.65 on the news. The partnership builds on a three-year clinical-stage collaboration that supported the SPS Biologics License Application process and manufacturing optimization.Stock TitanKyverna, ElevateBio Sign Miv-cel Supply AgreementKyverna Therapeutics and ElevateBio have signed a commercial manufacturing and supply agreement for miv-cel, Kyverna's autologous CD19-directed CAR T-cell therapy, to support U.S. commercial and global clinical supply. The agreement provides flexible and scalable manufacturing as Kyverna prepares for potential launches in stiff person syndrome and generalized myasthenia gravis, with a rolling BLA submission on track for completion in Q4 2026. If approved, miv-cel would become the first FDA-approved CAR T-cell therapy for an autoimmune disease and the first approved treatment for people living with SPS.BioSpaceKyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-celKyverna Therapeutics and ElevateBio announced a manufacturing agreement for miv-cel, Kyverna's CAR T-cell therapy, to support U.S. commercial and global clinical supply. The deal aims to enable potential launches in stiff person syndrome and generalized myasthenia gravis, with Kyverna on track to complete its rolling BLA submission in Q4 2026.Investing.comKyverna, ElevateBio sign manufacturing pact for miv-cel supply By Investing.comKyverna Therapeutics and ElevateBio announced a manufacturing agreement for U.S. commercial and global clinical supply of miv-cel, an autologous CD19-directed CAR T-cell therapy. The deal covers supply for potential launches in stiff person syndrome and generalized myasthenia gravis, with Kyverna on track to submit its Biologics License Application in Q4 2026.